Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Lower-income Patients are less likely to participate in clinical trials

2012 ASCO Annual Meeting

Published: 3 Jun 2012

Views: 4313

Rating:

Save

Dr Joseph Unger - SWOG Statistical Center, Seattle, USA

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Joseph Unger presented data from a national survey of cancer patients showing that income strongly predicts the likelihood a patient will participate in a clinical trial, which raises concern that lower-income patients don’t have equal access to clinical trials.

ecancerNews Coverage

Related Videos

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and...

Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects ( Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal )

Applying Choosing Wisely in radiation oncology in Africa

Dr Melinda Mushonga - Kingston General Hospital, Kingston, Canada

Applying Choosing Wisely in radiation oncology in Africa ( Dr Melinda Mushonga - Kingston General Hospital, Kingston, Canada )

The treatment of cervical cancer in the presence of HIV in Sub-Saharan Africa

Dr Ntokozo Ndlovu - University of Zimbabwe, Harare, Zimbabwe

The treatment of cervical cancer in the presence of HIV in Sub-Saharan Africa ( Dr Ntokozo Ndlovu - University of Zimbabwe, Harare, Zimbabwe )

Choosing Wisely conferences: Lessons learned and the way forward

Dr Omar Abdihamid - Garissa Cancer Centre, Garissa, Kenya

Choosing Wisely conferences: Lessons learned and the way forward ( Dr Omar Abdihamid - Garissa Cancer Centre, Garissa, Kenya )

Chairperson: Evidence Communication

Dr Hemant Malhotra - Sriram Cancer Center of the Mahatma Gandhi College...

Chairperson: Evidence Communication ( Dr Hemant Malhotra - Sriram Cancer Center of the Mahatma Gandhi College Hospital, Jaipur, India )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Durable effect of imatinib and metronomic chemotherapy with capecitabine in...

Dr Sana Al-Sukhun - Al Hyatt Oncology Practice, Amman, Jordan

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma ( Dr Sana Al-Sukhun - Al Hyatt Oncology Practice, Amman, Jordan )

African oncologists interaction with pharmaceutical industry

Prof Nazik Hammad - Queen's University, Kingston, Canada

African oncologists interaction with pharmaceutical industry ( Prof Nazik Hammad - Queen's University, Kingston, Canada )

More from ecancer